Donald Stone, MD
Ophthalmology · Spokane Valley, WANPI 1790744860
Payments from drug & device makers
What this record shows
12 manufacturers reported payments, led by US Retina LLC at 48.0% of the total. 2025 is the largest year on record at $461, 2.8 times the $166 reported in 2019.
Across 30 payments — averaging $46.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- US Retina LLC$667
- Biotissue Holdings Inc.$282
- Dompe US, Inc.$211
- AbbVie$48
- Bausch & Lomb Americas Inc.$41
- Lombart Brothers, Inc.$27
- plus $112 from 6 others
Across 22 payments — averaging $298.75 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Glaukos Corporation$7K
What the payments were for
- Food & beverage$72152%
- Ownership interest$66748%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| US Retina LLC | 6 | $667 |
| Biotissue Holdings Inc. | 5 | $282 |
| Dompe US, Inc. | 9 | $211 |
| AbbVie | 1 | $48 |
| Bausch & Lomb Americas Inc. | 2 | $41 |
| Lombart Brothers, Inc. | 1 | $27 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 1 | $23 |
| Lensar, Inc. | 1 | $22 |
| ANI Pharmaceuticals, Inc. | 1 | $20 |
| Sun Pharmaceutical Industries Inc. | 1 | $18 |
| Alcon | 1 | $16 |
| Shire North American Group Inc | 1 | $14 |
How this compares
$1,388 in reported general payments places this provider in the 60th percentile of 428 ophthalmology providers in Washington.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OxervateCenegermin-Bkbj | 22 | $519,012 |
| RestasisCyclosporine | 75 | $65,996 |
| Restasis MultidoseCyclosporine | 50 | $37,271 |
| XiidraLifitegrast | 47 | $32,877 |
| Prednisolone Acetate | 389 | $14,217 |
| Fluorometholone | 194 | $13,340 |
| Cyclosporine | 29 | $10,392 |
| Difluprednate | 70 | $7,024 |
| ZirganGanciclovir | 11 | $5,974 |
| Loteprednol Etabonate | 25 | $4,035 |
| Famciclovir | 11 | $3,439 |
| ValacyclovirValacyclovir Hcl | 83 | $2,813 |
| Doxycycline Hyclate | 45 | $2,419 |
| Tobramycin-DexamethasoneTobramycin/Dexamethasone | 39 | $1,921 |
| Ketorolac Tromethamine | 83 | $1,900 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Dompe US, Inc.Oxervate | $211 | $519,01222 claims |
| AbbVieRestasis, Restasis Multidose | $48 | $103,267125 claims |
| Bausch & Lomb Americas Inc.Xiidra, Zirgan | $41 | $38,85158 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCLoteprednol Etabonate | $23 | $4,03525 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 428 ophthalmology providers in Washington.
Other ophthalmology in Spokane Valley
- Mark KontosSpokane Valley$175K
- Christopher SturbaumSpokane Valley$30K
- Laura PerimanSeattle$1.7M
- Sheldon CowenSeattle$560K
- Todd SchneidermanSilverdale$200K
- Jennifer ChaoSeattle$188K
- Audrey RostovBellevue$155K
- John SamplesOlympia$115K
- Barbara SmitSpokane$110K
- Debarshi MustafiSeattle$85K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.